Roche NimbleGen and Biogemma Develop Enhanced Sequence Capture Technology for Wheat and Canola

MADISON, Wis.--(BUSINESS WIRE)-- Sequence Capture technology was pioneered by Roche NimbleGen (Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) with the initial products focused on human research. Subsequent developments have enabled the technology to be successfully transferred to rice and then adapted to maize. In January 2009, Roche NimbleGen and Biogemma announced their collaboration to develop a NimbleGen Sequence Capture protocol adapted to crops containing more complex genomes including polyploid crops such as wheat and rapeseed (canola). The goal of this partnership was to enhance capture performance on these complex species in order to achieve an enrichment rate that makes downstream sequencing more effective. The new NimbleGen Sequence Capture procedure was implemented and evaluated at Biogemma, and researchers are now well equipped for large-scale genomic marker discovery for wheat and rapeseed.

While former capture technologies displayed insufficient performance on complex polyploid genomes, the new NimbleGen Sequence Capture protocol developed by this collaboration has proven to be an efficient, reliable, fast, and cost-effective front-end method for targeted re-sequencing. The combined power of the Roche genomics portfolio was shown by employing the combination of NimbleGen Sequence Capture arrays with the GS FLX Titanium sequencing technology from 454 Life Sciences, a Roche company. Routine use of this complete target enrichment and sequencing solution by researchers at Biogemma has revealed that post-capture sequencing data are reliably comprised of sequences of interest, and that the long reads from the 454 Sequencing System facilitate discovery. Along with these enhancements, Biogemma has devised a downstream bioinformatic pipeline intended for read assembly and to efficiently deal with homeologs and paralogs for robust SNP identification.

NimbleGen Sequence Capture enabled this significant breakthrough in SNP discovery, in particular for species for which breeding efforts were thought to be slowed due to a lack of SNP markers, with the findings of this research presented to the scientific community during the last Plant and Animal Genome Conference in San Diego in January of 2010. Since then, several projects employing this enhanced Sequence Capture technology have been launched by Biogemma for the above-mentioned species. The development effort has also proven valuable for other species, as the protocol refinements also appear to make maize sequence capture more attainable. For these new research projects at Biogemma, several candidate genes are now under investigation for better understanding and future improval of several agronomical traits including disease resistance, yield, drought, and nitrogen use efficiency.

“We have been impressed by the speed with which Roche NimbleGen has performed the technical development expected” said Pascual Perez, CEO of Biogemma. “This improved capture technology is now used at Biogemma to optimize our marker development strategy for candidate genes from genomic and functional genomic studies, especially those from our detailed transcriptomic studies. We are now able to saturate genomic regions associated with agronomical traits with novel markers. As a suitable upstream step for current marker and marker assisted selection technologies, this breakthrough is very attractive for Biogemma’s shareholders, especially regarding species that haven’t been fully sequenced to date.”

“We also found improved capture, associated with long read sequencing of the 454 Sequencing System, allowed us to uncover intronic sequences while targeting only exons with an EST-based design. This provides researchers with access to previously uncharacterized genomic sequences that harbor higher rates of polymorphisms.” said Jean-Philippe Pichon, scientist at Biogemma.

‘We are excited with this collaboration that extends sequence capture technologies into research on complex plants such as wheat and canola,’ said Dr. Frank Pitzer, CEO of Roche NimbleGen. ‘This specific study truly shows the flexibility to quickly adapt our NimbleGen Sequence Capture technology to assist in unraveling researchers understanding of the genetic makeup of poorly characterized species and organisms.’

For more information on Roche NimbleGen, visit www.nimblegen.com

For more information on Biogemma, visit www.biogemma.com

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Biogemma
Biogemma is a leading agricultural biotech company in Europe involved in Genomics applied to Field Crops. Result of the merger of the biotech activity of three major seed business companies specialized in plant improvement, Vilmorin & Cie (Limagrain Group), Euralis and RAGT and with the help of two financial institutions Sofiproteol and Unigrain with the support of the technical agency Arvalis, the company is developing R&D programs with its partners, in field crops (Corn, Wheat, Sunflower and Rapeseed). Their primary focus is the greatest challenge in agriculture: to explain, explore and enrich the genetic diversity of those crops with the aims of yield improvement, low input of fertilizers, biotic and abiotic stresses tolerances and quality and speciality grain compounds. Biogemma is committed to using an environmentally responsible approach and the latest technology to enable crop breeders to develop innovative plant products.

For life science research only. Not for use in diagnostic procedures.

454,454 SEQUENCING, 454 LIFE SCIENCES, GS FLX TITANIUM and NIMBLEGEN are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
or
Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: [email protected]
or
Biogemma
Pascual Perez
Phone: +33 1 55 34 94 00
Email: [email protected]

KEYWORDS:   United States  Europe  North America  Switzerland

INDUSTRY KEYWORDS:   Stem Cells  Surgery  Health  Genetics  Hospitals  Medical Devices  Oncology  Pharmaceutical  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.